| Literature DB >> 33163124 |
Xiuli Sun1, Jinhe Jiang2, Yang Wang1,3, Shuying Liu1.
Abstract
INTRODUCTION: Historically traditional Chinese medicine (TCM) has been used as treatment during epidemics. During the recent COVID-19 pandemic patients evidence suggests that the use of TCM has provided health benefits and has been successfully used to control the spread of the disease in China. The aim of this study was to systematically explore the TCM formulae which have been used for the prevention and treatment of pneumonia or 'pestilence' to investigate their compatibility with the Chinese materia medica (CMM) and understand their potential mechanisms in the treatment of COVID-19.Entities:
Keywords: Anti-viral; Association rules analysis; COVID-19; Chinese materia medica; Network pharmacology; Traditional Chinese medicine
Year: 2020 PMID: 33163124 PMCID: PMC7598573 DOI: 10.1016/j.eujim.2020.101242
Source DB: PubMed Journal: Eur J Integr Med ISSN: 1876-3820 Impact factor: 1.314
High-frequency CMMs in prescriptions (Top 10)
| No. | Chinese name | Latin name | Frequency | Percentage (%) |
|---|---|---|---|---|
| 1 | Glycyrrhizae Radix Et Rhizoma | 84 | 49 | |
| 2 | Scutellariae Radix | 51 | 29 | |
| 3 | Platycodonis Radix | 45 | 26 | |
| 4 | Armeniacae Semen Amarum | 37 | 21 | |
| 5 | Lonicerae Japonicae Flos | 35 | 20 | |
| 6 | Gypsum Fibrosum | 34 | 20 | |
| 7 | Forsythiae Fructus | 33 | 19 | |
| 8 | Ephedrae Herba | 32 | 18 | |
| 9 | Rhei Radix Et Rhizoma | 30 | 17 | |
| 10 | Menthae Haplocalycis Herba | 28 | 16 |
High-frequency pair-CMMs in prescriptions (Top 10)
| No. | pair-CMMs | Frequency | Percentage (%) |
|---|---|---|---|
| 1 | 34 | 20% | |
| 2 | 28 | 16% | |
| 3 | 26 | 15% | |
| 4 | 25 | 14% | |
| 5 | 22 | 13% | |
| 6 | 21 | 12% | |
| 7 | 20 | 12% | |
| 8 | 20 | 12% | |
| 9 | 20 | 12% | |
| 10 | 20 | 12% |
High-frequency triple-CMMs in prescriptions
| No. | triple-CMMs | Frequency | Percentage (%) |
|---|---|---|---|
| 1 | 17 | 10% | |
| 2 | 16 | 9% | |
| 3 | 15 | 9% | |
| 4 | 15 | 9% | |
| 5 | 15 | 9% | |
| 6 | 14 | 8% | |
| 7 | 13 | 8% | |
| 8 | 13 | 8% | |
| 9 | 13 | 8% |
Fig. 1The scatter plot for rules (A) and CMMs association network (B) of prescription.
Fig. 2The CMMs-compound-target network of Group 2 (A) and Group 3 (B) prescriptions (: CMM, : compound, and : target; the larger the node, the higher the connectivity degree).
Fig. 3The PPI network of the target related to Group 2 (A) and Group 3 (C) prescriptions. The larger the node, the higher the connectivity degree, and the darker the color, the larger the betweenness centrality. The distribution of target proteins with the connectivity degree and betweenness centrality higher than the average value in Group 2 (B) and Group 3 (D) prescriptions.
Fig. 4The PPI cluster of Group 2 prescription and their related GO enrichment (B) and KEGG enrichment (C) analysis results.
Fig. 5The PPI cluster of Group 3 prescription and their related GO enrichment (B) and KEGG enrichment (C) analysis result.